The Cardiovascular Analysis Basis® (CRF®) is happy to announce the late-breaking scientific trials and science to be featured at TCT® 2024. Because the annual scientific symposium of CRF® and the world’s premier academic assembly specializing in interventional cardiovascular medication, TCT® 2024 can be held October 27-30 in Washington, D.C. on the Walter E. Washington Conference Middle.
For over three a long time, TCT® has been on the forefront of innovation, schooling, and collaboration in interventional cardiology, with a steadfast dedication to enhancing the survival and high quality of life for sufferers affected by coronary heart and vascular illness. Yearly, TCT® options groundbreaking analysis that instantly impacts affected person care and the way physicians deal with coronary heart illness.
Within the quickly evolving subject of medication, late-breaking trials are extremely anticipated and supply clinicians the chance to study new interventions, medication, strategies, and methods that might doubtlessly enhance affected person outcomes. The 25 research chosen for presentation at TCT® study the protection and effectiveness of minimally invasive strategies, prescription drugs, applied sciences, and gadgets that display potential to deal with or stop heart problems. Late-breaking trials can be introduced throughout the primary classes and highlighted throughout press conferences scheduled for Monday, October 28, Tuesday, October 29, and Wednesday, October 30.
Monday, October 28, 2024
EARLY TAVR: Transcatheter Aortic Valve Substitute for Asymptomatic Extreme Aortic Stenosis: Outcomes of the EARLY TAVR Trial
EVOLVED: Early Intervention in Sufferers With Asymptomatic Extreme Aortic Stenosis and Left Ventricular Myocardial Fibrosis
TAVR UNLOAD: Transcatheter Aortic Valve Substitute in Sufferers With Systolic Coronary heart Failure and Average Aortic Stenosis
DCB-BIF: Comparability of Noncompliant Balloon With Drug-Coated Balloon Angioplasty for Facet Department Stenosis After Provisional Stenting for Sufferers With True Coronary Bifurcation Lesions
HELP PCI: Early Administration of Heparin at First Medical Contact Versus within the Cath Lab for STEMI Sufferers Present process Main Percutaneous Coronary Intervention: A Multicenter, Randomized Trial
DRAMI: Randomized Comparability of Puncture Success Price Between Distal Radial Entry and Transradial Entry in Sufferers With ST-Elevation Myocardial Infarction
INFINITY-SWEDEHEART Advanced PCI: 1-Yr and Landmark 6–12 Month Medical Outcomes Amongst Sufferers With Advanced Lesion Subsets Handled with DynamX Bioadaptor In comparison with a Modern Drug Eluting Stent
CONFIRM-2: Synthetic Intelligence Enabled Quantitative CT Evaluation of Atherosclerosis and Main Adversarial Occasions: A Multi-Middle Worldwide Registry
Tuesday, October 29, 2024
ECLIPSE: A Massive-Scale, Randomized Trial of Orbital Atherectomy vs. Typical Balloon Angioplasty in Severely Calcified Coronary Arteries Previous to DES Implantation
CLEAR SYNERGY (OASIS 9): A 2×2 Factorial Randomized Managed Trial of Colchicine Versus Placebo and Spironolactone Versus Placebo in Sufferers With Myocardial Infarction: Outcomes of the Colchicine Factorial
PEERLESS: Massive-Bore Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for Remedy of Intermediate-Threat Pulmonary Embolism
SIRONA: Head-to-Head Comparability of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty within the Femoropopliteal Artery
Co-STAR: Colchicine in Sufferers With Aortic Stenosis Present process Transcatheter Aortic Valve Substitute: A Double-Blind Randomized Managed Trial
ACCESS TAVI: Randomized Comparability of Methods for Vascular Entry Closure After Transcatheter Aortic Valve Implantation
PROTECTED TAVR: US Subgroup: Cerebral Embolic Safety within the US Cohort of the PROTECTED TAVR Randomized Trial
RHEIA/PARTNER Pooled Evaluation in Girls: Transcatheter vs. Surgical Aortic Valve Substitute in Girls: A Pooled Evaluation of the RHEIA and PARTNER 3 Trials
ALIGN-AR 2 Yr: Two-Yr Outcomes of Transcatheter Aortic Valve Substitute With JenaValve Trilogy™ in Excessive Surgical Threat Sufferers With Average-to-Extreme or Extreme Native Aortic Regurgitation
Wednesday, October 30, 2024
TRISCEND II: Randomized Comparability of Transcatheter Valve Substitute vs. Optimum Medical Remedy for Extreme Tricuspid Regurgitation
FAVOR III Europe: Quantitative Movement Ratio or Fractional Movement Reserve for Guiding Coronary Revascularization
FLASH: Synthetic Intelligence-Primarily based Totally Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Steering for Coronary Stent Implantation: A Multicenter, Randomized Managed Non-Inferiority Trial
TARGET IV: Worldwide Multicenter Randomized Evaluation of the Firehawk® Rapamycin Eluting Coronary Stent System
TARGET DAPT: Potential, Multicenter, Open-Label, Randomized Managed Trial of 3-Month Versus 12-Month Twin Antiplatelet Remedy After Implantation of the Biodegradable Polymer Firehawk® Sirolimus-Eluting Coronary Stent
CLEAR-IE: Outcomes of Percutaneous Mechanical Aspiration in Proper-Sided Infective Endocarditis: A Multicenter Registry
CLASP IID 2 Yr RCT and Registry: Two-Yr Outcomes of Transcatheter Edge-to-Edge Restore for Degenerative Mitral Regurgitation
MATTERHORN: Atrial MR Subgroup Transcatheter Restore Versus Surgical procedure in Atrial Mitral Regurgitation: Outcomes From the MATTERHORN Trial
Media are invited to attend TCT® and may apply for media credentials at: https://tct2024.crfconferences.com/press-registration.
Obtain updates on X at https://x.com/TCTConference and https://x.com/crfheart.
Supply:
Cardiovascular Analysis Basis
